Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of C-GAP for relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma
ChiCTR1800020344Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine, filgrastim, cytarabine and pegaspargase in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: overall survival and relapse-free survival. Started Jan 2019; status: recruiting.
02
Drugs
cladribinefilgrastimcytarabinepegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on ChiCTR1800020344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020344.